VANCOUVER, Sept. 25, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the “Company“), a biotech firm targeted on discovery and improvement of novel psychedelic-derived therapeutics to unravel main undertreated well being issues, pronounces that will probably be consolidating all of the issued and excellent widespread shares of the Company (“Common Shares“) on the premise of one (1) publish consolidation Common Share for every thirty (30) pre consolidation Common Shares (the “Consolidation“).
The Corporation’s board of administrators set September 30, 2022 because the efficient date of the Consolidation. Trading of the Common Shares on a post-Consolidation foundation on the Canadian Securities Exchange (the “CSE“) will start on or about October 3, 2022. The Company’s title and buying and selling image will stay unchanged.
The 39,592,344 Common Shares at present issued and excellent shall be decreased to roughly 1,319,744 Common Shares on a post-Consolidation foundation. No fractional shares shall be issued. Any fractional curiosity in Common Shares shall be rounded as much as the closest complete Common Share.
Letter of transmittals shall be mailed to registered Shareholders and registered Shareholders shall be required to deposit their share certificates(s), along with the duly accomplished letter of transmittal, with Computershare Investor Services Inc., the Company’s registrar and switch agent. Non-registered Shareholders holding Common Shares by means of an middleman (a securities dealer, seller, financial institution or monetary establishment) needs to be conscious that the middleman could have totally different procedures for processing the Consolidation than people who shall be put in place by the Company for registered Shareholders. If Shareholders maintain their Common Shares by means of intermediaries and have questions on this regard, they’re inspired to contact their intermediaries.
Outstanding inventory choices and share buy warrants may also be adjusted by the Consolidation ratio and the respective train costs of excellent choices and share buy warrants shall be adjusted accordingly.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech firm targeted on the invention and improvement of novel psychedelic-derived therapeutics to unravel widespread and underserved well being issues, together with alcohol use dysfunction. Its main goal is to analysis and develop psychedelic-based compounds and try and commercialize them as regulated medicines, meals or dietary supplements.
The Company’s mental portfolio at present consists of seven patent households. The Company intends to hunt further patents for its compounds at any time when warranted and can stay opportunistic concerning the acquisition of further mental property to construct its portfolio.
Shares of Clearmind are listed for buying and selling on the Canadian Securities Exchange below the image “CMND“, the Frankfurt Stock Exchange below the image “CWYO” and on the OTC Markets below the image “CMNDF“.
For additional data, please contact:
Investor Relations,
Email: make [email protected]
Telephone: (604) 260-1566
General Inquiries,
[email protected]
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This information launch could comprise forward-looking statements and data based mostly on present expectations. These statements shouldn’t be learn as ensures of future efficiency or outcomes. Such statements contain identified and unknown dangers, uncertainties and different components that will trigger precise outcomes, efficiency or achievements to be materially totally different from these implied by such statements. Such statements embody submission of the related documentation throughout the required timeframe to the satisfaction of the related regulators and elevating ample financing to finish the Company’s business technique. There isn’t any certainty that any of these occasions will happen. Although such statements are based mostly on administration’s cheap assumptions, there will be no assurance that such assumptions will show to be appropriate. We assume no duty to replace or revise them to replicate new occasions or circumstances.
Investing into early-stage firms inherently carries a excessive diploma of threat, and funding into securities of the Company shall be thought of extremely speculative.
This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase, nor shall there be any sale of the securities in any province during which such provide, solicitation or sale can be illegal. The securities issued, or to be issued, below the Private Placement haven’t been, and won’t be, registered below the United States Securities Act of 1933, as amended, and will not be supplied or offered within the United States absent registration or an relevant exemption from registration necessities.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that time period is outlined within the insurance policies of the CSE) accepts duty for the adequacy or accuracy of this launch.
